Tango Cuts 14% of Workforce, Halts Preclinical Work to Focus on PRMT5 Assets
TNGX has more than doubled off its 52-week low of $6.69 on elevated volume (2.0× avg).
Summary
Tango approved a strategic reprioritization of R&D that cuts roughly 14% of its workforce, with most of the reductions coming from the research group. The company will stop certain preclinical and research activities and redirect resources to translational work and its PRMT5 programs, vopimetostat and TNG456. This follows the Q2 disclosure that it was already deprioritizing two early-stage programs to concentrate on lead oncology assets, and it lands the same morning as the 82% response rate data for vopimetostat plus daraxonrasib in pretreated pancreatic cancer. The cash saved extends runway on a pipeline now narrowed to a single target class, which raises concentration risk if the PRMT5 readouts disappoint.
At the time of this announcement, TNGX was trading at $29.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $6.69 to $34.39. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.